PURPOSE: The aim of this study was to evaluate the prognostic influence of epithelial cell adhesion molecule (EpCAM) in an unselected cohort of ovarian cancer (OC) patients. METHODS: Expression of EpCAM was determined by immunohistochemistry in an unselected cohort of 117 patients with OC. Univariable and multivariable Cox regression analyses adjusted for age, tumor stage, histological grading, histological subtype, postoperative tumor burden and completeness of chemotherapy were performed in order to determine the prognostic influence of EpCAM. The Kaplan-Meier method is used to estimate survival rates. RESULTS: Univariable Cox regression analysis showed that overexpression of EpCAM is associated with favorable prognosis in terms of progression-free survival (PFS) (p = 0.011) and disease-specific survival (DSS) (p = 0.003). In multivariable Cox regression analysis, overexpression of EpCAM retains its significance independent of established prognostic factors for longer PFS [hazard ratios (HR) 0.408, 95 % confidence interval (CI) 0.197-0.846, p = 0.003] but not for PFS (HR 0.666, 95 % CI 0.366-1.212, p = 0.183). Kaplan-Meier plots demonstrate an influence on 5-year PFS rates (0 vs. 27.6 %, p = 0.048) and DSS rates (11.8 vs. 54.0 %, p = 0.018). CONCLUSIONS: These findings support the hypothesis that the expression of EpCAM is associated with favorable prognosis in OC.
PURPOSE: The aim of this study was to evaluate the prognostic influence of epithelial cell adhesion molecule (EpCAM) in an unselected cohort of ovarian cancer (OC) patients. METHODS: Expression of EpCAM was determined by immunohistochemistry in an unselected cohort of 117 patients with OC. Univariable and multivariable Cox regression analyses adjusted for age, tumor stage, histological grading, histological subtype, postoperative tumor burden and completeness of chemotherapy were performed in order to determine the prognostic influence of EpCAM. The Kaplan-Meier method is used to estimate survival rates. RESULTS: Univariable Cox regression analysis showed that overexpression of EpCAM is associated with favorable prognosis in terms of progression-free survival (PFS) (p = 0.011) and disease-specific survival (DSS) (p = 0.003). In multivariable Cox regression analysis, overexpression of EpCAM retains its significance independent of established prognostic factors for longer PFS [hazard ratios (HR) 0.408, 95 % confidence interval (CI) 0.197-0.846, p = 0.003] but not for PFS (HR 0.666, 95 % CI 0.366-1.212, p = 0.183). Kaplan-Meier plots demonstrate an influence on 5-year PFS rates (0 vs. 27.6 %, p = 0.048) and DSS rates (11.8 vs. 54.0 %, p = 0.018). CONCLUSIONS: These findings support the hypothesis that the expression of EpCAM is associated with favorable prognosis in OC.
Authors: Gilbert Spizzo; Philip Went; Stephan Dirnhofer; Peter Obrist; Holger Moch; Patrick A Baeuerle; Elisabeth Mueller-Holzner; Christian Marth; Guenther Gastl; Alain G Zeimet Journal: Gynecol Oncol Date: 2006-05-06 Impact factor: 5.482
Authors: Narendra V Sankpal; Michael W Willman; Timothy P Fleming; John D Mayfield; William E Gillanders Journal: Cancer Res Date: 2009-01-13 Impact factor: 12.701
Authors: Viola A Heinzelmann-Schwarz; Margaret Gardiner-Garden; Susan M Henshall; James Scurry; Richard A Scolyer; Michael J Davies; Matthias Heinzelmann; Larry H Kalish; Anish Bali; James G Kench; Lyndal S Edwards; Patricia M Vanden Bergh; Neville F Hacker; Robert L Sutherland; Philippa M O'Brien Journal: Clin Cancer Res Date: 2004-07-01 Impact factor: 12.531
Authors: David B Seligson; Allan J Pantuck; Xueli Liu; Yunda Huang; Steven Horvath; Matthew H T Bui; Ken-ryu Han; Adrian J L Correa; Mervi Eeva; Sheila Tze; Arie S Belldegrun; Robert A Figlin Journal: Clin Cancer Res Date: 2004-04-15 Impact factor: 12.531
Authors: Meri Varga; Peter Obrist; Stephan Schneeberger; Gilbert Mühlmann; Christina Felgel-Farnholz; Dominic Fong; Mathias Zitt; Thomas Brunhuber; Georg Schäfer; Guenther Gastl; Gilbert Spizzo Journal: Clin Cancer Res Date: 2004-05-01 Impact factor: 12.531
Authors: I Songun; S V Litvinov; C J H van de Velde; S T Pals; J Hermans; J H J M van Krieken Journal: Br J Cancer Date: 2005-05-09 Impact factor: 7.640
Authors: Marco Johannes Battista; Marcus Schmidt; Sina Jakobi; Cristina Cotarelo; Katrin Almstedt; Anne-Sophie Heimes; Georgios-Marios Makris; Veronika Weyer; Antje Lebrecht; Gerald Hoffmann; Michael Eichbaum Journal: Oncol Lett Date: 2016-07-21 Impact factor: 2.967
Authors: Marco Johannes Battista; Kristina Goetze; Marcus Schmidt; Cristina Cotarelo; Veronika Weyer-Elberich; Annette Hasenburg; Wolfgang Mueller-Klieser; Stefan Walenta Journal: J Cancer Res Clin Oncol Date: 2016-06-24 Impact factor: 4.553